OBJECTIVE: We conducted a multicenter phase II trial to assess the efficacy and toxicity of docetaxel and carboplatin combination as neoadjuvant therapy for stage II or III breast cancer (BC). METHODS: Patients received 75 mg/m of docetaxel and AUC 6 of carboplatin on day 1 followed by pegfilgrastim on day 2, every 14 days for 4 cycles, followed by definitive breast surgery. The primary endpoint was the proportion of patients achieving pathologic complete remission (pCR), defined as disappearance of all invasive and in situ tumors in the breast and axilla after chemotherapy. RESULTS: A total of 57 women (median age, 53 y) were enrolled. Thirty-eight (67%) had ER+, 31 (54%) PR+, and 6 (11%) HER2+ disease; 9 had triple negative BC (TNBC). Forty-three (75%; 95% confidence interval, 62%-86%) of 57 eligible patients had clinical response (15 clinical complete response, 28 clinical partial response). Nine (16%; 90% confidence interval, 10%-28%) patients achieved pCR. Four of 9 (44%) patients with TNBC achieved pCR. Thrombocytopenia (5%) was the only grade 4 adverse event. The most common grade 3 adverse events were thrombocytopenia (19%), fatigue (12%), and anemia (9%). CONCLUSIONS: Four cycles of 2-weekly Docetaxel and Carboplatin are feasible with acceptable toxicity and a pCR rate of 16%. This regimen can be considered for neoadjuvant therapy of BC, particularly for patients not eligible for anthracycline therapy. A high pCR rate of 44% noted in a subset of patients with TNBC is encouraging and needs to be validated in large prospective trials.
OBJECTIVE: We conducted a multicenter phase II trial to assess the efficacy and toxicity of docetaxel and carboplatin combination as neoadjuvant therapy for stage II or III breast cancer (BC). METHODS:Patients received 75 mg/m of docetaxel and AUC 6 of carboplatin on day 1 followed by pegfilgrastim on day 2, every 14 days for 4 cycles, followed by definitive breast surgery. The primary endpoint was the proportion of patients achieving pathologic complete remission (pCR), defined as disappearance of all invasive and in situ tumors in the breast and axilla after chemotherapy. RESULTS: A total of 57 women (median age, 53 y) were enrolled. Thirty-eight (67%) had ER+, 31 (54%) PR+, and 6 (11%) HER2+ disease; 9 had triple negative BC (TNBC). Forty-three (75%; 95% confidence interval, 62%-86%) of 57 eligible patients had clinical response (15 clinical complete response, 28 clinical partial response). Nine (16%; 90% confidence interval, 10%-28%) patients achieved pCR. Four of 9 (44%) patients with TNBC achieved pCR. Thrombocytopenia (5%) was the only grade 4 adverse event. The most common grade 3 adverse events were thrombocytopenia (19%), fatigue (12%), and anemia (9%). CONCLUSIONS: Four cycles of 2-weekly Docetaxel and Carboplatin are feasible with acceptable toxicity and a pCR rate of 16%. This regimen can be considered for neoadjuvant therapy of BC, particularly for patients not eligible for anthracycline therapy. A high pCR rate of 44% noted in a subset of patients with TNBC is encouraging and needs to be validated in large prospective trials.
Authors: Edith A Perez; Vera J Suman; Tom R Fitch; James A Mailliard; James N Ingle; John T Cole; Michael H Veeder; Patrick J Flynn; Daniel J Walsh; Ferdinand K Addo Journal: Oncology Date: 2005-08-23 Impact factor: 2.935
Authors: Lisa A Carey; Charles M Perou; Chad A Livasy; Lynn G Dressler; David Cowan; Kathleen Conway; Gamze Karaca; Melissa A Troester; Chiu Kit Tse; Sharon Edmiston; Sandra L Deming; Joseph Geradts; Maggie C U Cheang; Torsten O Nielsen; Patricia G Moorman; H Shelton Earp; Robert C Millikan Journal: JAMA Date: 2006-06-07 Impact factor: 56.272
Authors: Marjorie C Green; Aman U Buzdar; Terry Smith; Nuhad K Ibrahim; Vicente Valero; Marguerite F Rosales; Massimo Cristofanilli; Daniel J Booser; Lajos Pusztai; Edgardo Rivera; Richard L Theriault; Cynthia Carter; Debra Frye; Kelly K Hunt; W Fraser Symmans; Eric A Strom; Aysegul A Sahin; William Sikov; Gabriel N Hortobagyi Journal: J Clin Oncol Date: 2005-08-08 Impact factor: 44.544
Authors: Valentina Guarneri; Kristine Broglio; Shu-Wan Kau; Massimo Cristofanilli; Aman U Buzdar; Vicente Valero; Thomas Buchholz; Funda Meric; Lavinia Middleton; Gabriel N Hortobagyi; Ana M Gonzalez-Angulo Journal: J Clin Oncol Date: 2006-03-01 Impact factor: 44.544
Authors: H M Kuerer; L A Newman; T L Smith; F C Ames; K K Hunt; K Dhingra; R L Theriault; G Singh; S M Binkley; N Sneige; T A Buchholz; M I Ross; M D McNeese; A U Buzdar; G N Hortobagyi; S E Singletary Journal: J Clin Oncol Date: 1999-02 Impact factor: 44.544
Authors: W J Gradishar; S B Wedam; M Jahanzeb; J Erban; S A Limentani; K-T Tsai; S R Olsen; S M Swain Journal: Ann Oncol Date: 2005-05-19 Impact factor: 32.976
Authors: Harry D Bear; Stewart Anderson; Roy E Smith; Charles E Geyer; Eleftherios P Mamounas; Bernard Fisher; Ann M Brown; Andre Robidoux; Richard Margolese; Morton S Kahlenberg; Soonmyung Paik; Atilla Soran; D Lawrence Wickerham; Norman Wolmark Journal: J Clin Oncol Date: 2006-04-10 Impact factor: 44.544
Authors: Ewa Mrózek; Rachel Layman; Bhuvaneswari Ramaswamy; Maryam Lustberg; Andrea Vecchione; Michael V Knopp; Charles L Shapiro Journal: Clin Breast Cancer Date: 2014-02-20 Impact factor: 3.225
Authors: Alessandra Cataldo; Douglas G Cheung; Andrea Balsari; Elda Tagliabue; Vincenzo Coppola; Marilena V Iorio; Dario Palmieri; Carlo M Croce Journal: Oncotarget Date: 2016-01-05
Authors: Oluwadamilola M Fayanju; Yi Ren; Samantha M Thomas; Rachel A Greenup; Terry Hyslop; E Shelley Hwang; John H Stewart Journal: JNCI Cancer Spectr Date: 2019-12-16